Moderna Inc (MRNA)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Moderna Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 2 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 54.80 $ — 55% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
5 of 10 Solid growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -53.1% failed
- More than 10% revenue growth is expected for the coming year 20.5% passed
- Share count grows by less than 3% a year -2.2% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -145.5% failed
- Gross margin at 40% or higher and without meaningful erosion 55.4% passed
- Goodwill from acquisitions does not grow faster than revenue 0.4% passed
- Net debt below twice EBITDA 3,883 m net cash passed
- Operating cash flow covers the profits of the last three years 3,102 m failed
- Return on capital at 15% or higher, or up versus two years ago -29.7% failed
- Insiders hold at least 10% or are net buyers 7.3% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 9.7% below the current price.
- Consensus
- Hold
- Analyst Ratings
- 27
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -8.74 | -10.55 – -8.00 | 2,099 | -18.8% | 20 |
| 12/31/2027 | -4.97 | -7.11 – -3.24 | 2,424 | 44.2% | 19 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -2.91 | -629.50 | 956 | -66.00 | -117.20 | 825 | 303 |
| 2025: Q1 | -2.52 | – | 107 | -35.90 | -907.50 | -1,037 | -1,164 |
| 2025: Q2 | -2.13 | – | 142 | -35.70 | -581.00 | -919 | -922 |
| 2025: Q3 | -0.51 | -1,674.00 | 1,016 | -45.20 | -19.70 | -847 | -880 |
| 2025: Q4 | -2.11 | – | 678 | -29.10 | -121.80 | 951 | 912 |
| 2026: Q1 | -3.40 | – | 389 | 263.60 | -345.20 | -630 | -692 |
| 2026: Q2 | -1.97 | 7.50 | 145 | 2.10 | -539.30 | -526 | -563 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 108 | -224 | -216 | -0.58 | 67 | 842 | 1,417 |
| 2017 | 206 | -269 | -256 | -0.68 | -331 | 625 | 1,084 |
| 2018 | 123 | -413 | -385 | -4.74 | -331 | 1,530 | 1,962 |
| 2019 | 48 | -546 | -514 | -1.55 | -459 | 1,175 | 1,589 |
| 2020 | 274 | -763 | -747 | -1.96 | 2,027 | 2,561 | 7,337 |
| 2021 | 17,736 | 13,296 | 12,202 | 28.31 | 13,620 | 14,145 | 24,669 |
| 2022 | 18,875 | 9,420 | 8,362 | 20.10 | 4,981 | 19,123 | 25,858 |
| 2023 | 6,848 | -4,239 | -4,714 | -12.34 | -3,118 | 13,854 | 18,426 |
| 2024 | 3,199 | -3,945 | -3,561 | -9.27 | -3,004 | 10,901 | 14,142 |
| 2025 | 1,944 | -3,074 | -2,822 | -7.25 | -1,873 | 8,650 | 12,338 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Moderna, Inc. ist ein Biotechnologieunternehmen, das mRNA-Medikamente in den USA, Europa und international anbietet.
| Employees | 4,700 |
|---|---|
| Headquarters | Cambridge, MA |
| Address | 325 Binney Street, 02142 Cambridge, United States |
| Phone | 617 714 6500 |
| Website | modernatx.com |
| IPO Date | 7. Dec 2018 |
| ISIN | US60770K1079 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Stéphane Bancel M.B.A. | CEO & Director | 1973 |
| Stephen Hoge M.D. | President | 1976 |
| James M. Mock | Chief Financial Officer | 1977 |
| Shannon Thyme Klinger J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
| Jerh Collins Ph.D. | Chief Technical Operations & Quality Officer | 1966 |
| Lavina Talukdar CFA | Senior VP & Head of Investor Relations | 1974 |
| Chris Ridley | VP & Global Head of Communications | – |
| Tracey Franklin | Chief People & Digital Technology Officer | 1980 |
| Charbel Haber M.P.H., Ph.D. | Senior VP & Head of Global Regulatory Science | – |
| Patrick Norman Bergstedt | Senior Vice President of Commercial Vaccines | 1962 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 15. Jul 2026 | Hoge Stephen | President | Sell | 53,336 | 67.60 | 3,605,514 |
| 15. Jul 2026 | Hoge Stephen | President | Other | 16,110 | 19.15 | 308,507 |
| 15. Jul 2026 | Hoge Stephen | President | Other | 37,226 | 19.15 | 712,878 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.